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Abstract
Background: The use of antracycline (ANT) in breast cancer has been associated with adverse 
cardiac events. Two-dimensional (2D) strain imaging (SI) can provide a more sensitive measu-
re of altered left ventricular (LV) systolic function. We aimed to evaluate the preventive effect of 
carvedilol administration assessed by SI in a patient with breast cancer treated with ANT.
Methods: Patients receiving ANT were randomly assigned to the carvedilol- or placebo-
-receiving group. Each received an echocardiographic examination with conventional 2D 
echocardiography, pulsed tissue Doppler, and 2D SI prior to and 6 months post ANT treatment.
Results: During the 6-month follow-up period there were no patient deaths or interrupted 
chemotherapy treatments due to doxorubicin-induced cardiotoxicity. Both left ventricular ejec-
tion fraction (LVEF) and fractional shortening (FS) were within normal limits for all patients 
before and after ANT therapy. EF, FS and LV dimensions were measured using M-mode echo-
cardiography and found to be similar in both groups before and after ANT therapy. The mean 
EF, FS, and LV echocardiograph baseline and control dimensions were similar in both groups 
after 6 months. Though baseline SI parameters were similar between the groups, there was  
a significant decrease in LV basal septal and basal lateral peak systolic strain in the control 
group compared to the carvedilol group.
Conclusions: These results indicate that carvedilol has a protective effect against the cardio-
toxicity induced by ANT. (Cardiol J 2014; 21, 5: 509–515)
Key words: strain imaging, antracycline induced cardiotoxicity, echocardiography, 
carvedilol, beta-blocker
Introduction
Worldwide, breast cancer is a major public 
health problem with a lifetime risk of 1 in 10 and 
a mortality of approximately 1 in 33 [1]. Antracycli-
nes (ANT) are potent, broad-spectrum antineopla-
stic agents used widely in the treatment of breast 
cancer. Their introduction has led to improved 
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survival rates, but their therapeutic success is li-
mited by potentially life-threatening cardiotoxicity 
[2–4]. Although cardiotoxicity is a well-known side 
effect of ANT, detection of subclinical myocardial 
contractility impairment at a latent stage is difficult. 
The adopted diagnostic approach to detect cardiac 
damage is based primarily upon the estimation of 
left ventricular (LV) ejection fraction (EF) or fra-
ctional shortening (FS). Preclinical identification of 
LV dysfunction is crucial, as early therapy will allow 
complete recovery. M-mode echocardiography ima-
ging allows the assessment of muscle deformation, 
but has limited value in determining the number of 
myocardial segments since it allows deformation 
measurement in only the radial direction. Thus, it 
has been suggested that LV contractile function 
assessment be conducted using standard M-mode 
echocardiography systolic performance overesti-
mates [5]. However, strain rate imaging can be used 
to quantify local myocardial deformation at a high 
temporal resolution. Recent studies have demon-
strated the utility of strain imaging (SI) for the early 
detection of ANT-induced cardiomyopathy prior to 
alterations in conventional LVEF. 
The mechanisms of ANT-induced cardiotoxi-
city (AIC) include the formation of free reactive 
oxygen radicals, direct DNA damage, apoptosis, the 
activation of immune reactions in the heart, chan-
ges in calcium transport, histamine release, and 
coagulation system activation leading to coronary 
artery thrombosis [6]. Carvedilol is a nonselective, 
adrenergic blocker which also has antioxidant, anti-
-apoptotic and vasodilating properties. Considering 
its antioxidant and anti-apoptotic effects, carvedilol 
may also be beneficial for the prevention of AIC, 
yet few clinical trials of the prophylactic role of 
carvedilol on AIC have been conducted [7, 8]. In 
this study, we evaluated the preventive effect of 
carvedilol using strain imaging in patients with 
breast cancer treated with ANT. 
Methods
This prospective and randomized study consi-
sted of 80 female patients with breast cancer and 
anticipated ANT therapy, consecutively admitted 
to the Medical Oncology Department, Institute 
of Oncology, Istanbul University between 2012 
and 2013. Exclusion criteria included previous 
chemotherapy or radiotherapy; cardioprotective 
drug use, such as angiotensin-converting enzyme 
inhibitors, angiotensin receptor blockers, calcium 
channel blockers, statins, aldosterone receptor an-
tagonist, and other beta-blockers; the presence of 
any cardiac disease detected upon baseline evalua-
tion and echocardiography; and a history of chronic 
disease, such as diabetes, hypertension, chronic 
renal or hepatic failure, and  any contraindication 
to carvedilol use. Following study enrollment, par-
ticipants underwent a cardiac evaluation, a standard 
electrocardiogram (ECG), a conventional echocar-
diography and SI. Eligible patients were randomly 
assigned to either the carvedilol or control group 
according to a computer-generated sequence. The 
carvedilol group was administered a dose of 12.5-mg 
oral carvedilol prior to computed tomography, and 
followed by an oral carvedilol maintenance dose of 
12.5 mg daily for 6 months during chemotherapy. 
The control group did not receive any drug that 
could have cardioprotective effect. 
The study was approved by the ethics com-
mittee of the Istanbul School of Medicine, Istanbul 
University. All patients provided written informed 
consent.
Echocardiography
Echocardiography was performed using the Vi-
vid 7 echocardiography device (General Electrics, 
Milwaukee, WI, USA) tuned to a middle-range fre-
quency (3–8 MHz) broadband transducer. Diameter 
and EF were calculated according to the American 
Society of Echocardiography guidelines [9]. A pul-
sed-Doppler transmitral flow velocity profile was 
obtained from the apical 4-chamber view, and the 
sample volume was positioned immediately below 
the mitral valve leaflets. The following parameters 
were assessed: peak transmitral flow velocity in 
early diastole (peak E), peak transmitral flow velo-
city in late diastole (peak A), E/A ratio, isovolumic 
relaxation time, and isovolemic contraction time.
Strain imaging
Color-coded tissue Doppler data were acqui-
red and stored as cine-loops. Both tissue velocity 
imaging (TVI) and SI measures were obtained from 
off-line analysis of stored loops by using custom 
software (Echopac, GE Systems, Oslo, Norway). 
Pulsed TVI analysis of the mitral annulus was 
performed in the apical 4-chamber view. A 5-mL 
sample volume was placed at the septal and lateral 
sites of the annulus. Settings were adjusted for 
a frame rate between 120 Hz and 180 Hz, and 
a cineloop of 3 to 5 consecutive heart beats was 
recorded. TVI measures included peak systolic my-
ocardial velocity, early and late diastolic myocardial 
velocities and their ratio at the basal segments of 
the LV lateral and septal walls. Care was taken to 
obtain an ultrasound beam parallel to the direction 
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of the mitral annulus motion. SI measures included 
peak systolic strain and strain rate, peak early and 
late diastolic strain rate at the basal segments 
of the LV lateral and septal walls, as SI is angle-
-dependent and longitudinal velocities are highest 
in the basal LV segments and diminish toward the 
apex. For all strain parameter measurements, the 
sample volume, oval and 6 × 12 mm in size, was 
placed in the basal inner half of the LV myocardium 
at the septum and the lateral wall to keep the angle 
between the Doppler beam and the endocardium 
smaller than 30°. The narrowest possible image 
sector angle was used to achieve the maximum 
color Doppler frame rate. The frame rates ranged 
154–184 fps. Strain rate was expressed as 1/s. The 
strain data were expressed as negative percentage 
values and measured from systolic strain curves. 
All TVI and SI measurements were calculated 
from 3 consecutive cycles and the average of 
3 measurements was recorded. The intra-observer 
variability for strain was 3.7 ± 4.2%.
Statistical analysis
Statistical analysis was performed with SPSS 
17.0 for Windows (SPSS, Chicago, IL, USA). Con-
tinuous data are expressed as means ± standard 
deviation, and categorical data as percentages. 
Student’s t-test was performed to compare unpai-
red samples. Differences between groups before 
and after therapy were compared with a paired 
t-test. The results are presented as relative risks 
(RR) with 95% confidence intervals (CI). A value 
of p < 0.05 was considered to indicate statistical 
significance. The power analysis revealed that with 
this sample size (n = 40 vs. n = 40), the power 
level of this study was more than 0.90 for all SI 
parameters.
Results
Baseline characteristics are shown in Table 1. 
There were no significant differences between the 
groups in terms of age, body mass index, hemo-
globin levels, systolic and diastolic pressure. The 
cumulative ANT chemotherapy doses were similar 
between the groups (523.3 mg/m2 in the control 
group, 535.6 mg/m2 in the carvedilol group). No 
patients died or interrupted chemotherapy due 
to doxorubicin-induced cardiotoxicity during the 
follow-up period.
Table 1. Baseline characteristics and echocardiographic findings before anthracycline therapy.
Control group (n = 40) Carvedilol group (n = 40) P 
Age [years] 52.9 ± 11.2 54.3 ± 9.3 NS
Body mass index [kg/m2] 22.9 ± 2.4 23.5 ± 2.1 NS
Systolic blood pressure [mm Hg] 121 ± 26 114 ± 10 NS
Diastolic blood pressure [mm Hg] 74 ± 29 74 ± 10 NS
Hemoglobin [g/dL] 13.8 ± 3.2 13.2 ± 4.1 NS
Left atrium diameter [mm] 32.3 ± 5.1 32.6 ± 4.8 NS
Interventricular septum diameter [mm] 10.3 ± 1.3 10.2 ± 1.1 NS
Posterior wall diameter [mm] 9.4 ± 1.2 9.1 ± 1.4 NS
Left ventricular diastolic size [mm] 44.3 ± 3.1 45.1 ± 4.2 NS
Left ventricular systolic size [mm] 27.1 ± 6.1 28.3 ± 4.3 NS
Ejection fraction 65 ± 4.5 66 ± 6.1 NS
Fractional shortening 40.6 ± 5.1 41.1 ± 4.9 NS
E [m/s] 79.4 ± 18 76 ± 14 NS
A 68 ± 19 65 ± 11 NS
Isovolumic relaxation time 65.3 ± 18.9 63.4 ± 17.2 NS
E/A 1.1 ± 0.3 1.18 ± 0.4 NS
Septal S [mm] 7.1 ± 1.2 7.2 ± 1.3 NS
Lateral S [mm] 8.8 ± 2.1 9.1 ± 1.7 NS
Septal SSR [s–1] 0.94 ± 0.2 0.92 ± 0.14 NS
Lateral SSR [s–1] 1.1 ± 0.18 1.04 ± 0.21 NS
Septal SS [%] 19.3 ± 4.1 20.2 ± 3.2 NS
Lateral SS [%] 17.3 ± 3.2 17.8 ± 5.1 NS
SSR — systolic strain rate; SS — peak systolic strain; NS — non significant
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Echocardiography
LVEF and FS were within normal limits in all 
patients after ANT therapy. EF, FS and LV dimen-
sions measured by M-mode echocardiography were 
similar in all groups following ANT therapy (Table 2). 
Additionally, the mean EF, FS, and LV dimensions 
of both groups were similar at baseline and con-
trol echocardiography after 6 months (Table 3). 
The diastolic function parameters showed no sig-
nificant differences between groups following ANT 
therapy, with the exception of isovolumic relaxation 
time (Table 2). 
Table 2. M-mode echocardiographic and strain imaging findings after anthracycline therapy.
Control group (n = 40) Carvedilol group (n = 40) P 
Left atrium diameter [mm] 34.3 ± 6.1 33.4 ± 5.8 NS
Interventricular septum diameter [mm] 10.1 ± 1.2 10.3 ± 0.9 NS
Posterior wall diameter [mm] 9.3 ± 1.1 9.2 ± 1.5 NS
Left ventricular diastolic size [mm] 44.1 ± 4.1 44.6 ± 3.2 NS
Left ventricular systolic size [mm] 27.6 ± .5.1 28.1 ± 4.3 NS
Ejection fraction 63.3 ± 4.8 64.1 ± 5.1 NS
Fractional shortening 40.8 ± 5 40.1 ± 4.5 NS
E [m/s] 78.8 ± 18.1 75.3 ± 14.2 NS
A 69 ± 16 65.3 ± 11 NS
Isovolumic relaxation time 71.3 ± 16.8 61.4 ± 17.2 0.01
E/A 1.09 ± 0.4 1.17 ± 0.3 NS
Septal S 6.9 ± 1 7.2 ± 0.9 NS
Lateral S 8.6 ± 1.8 9 ± 2.1 NS
Septal SSR [s–1] 0.7 ± 0.14 0.94 ± 0.22 < 0.005
Lateral SSR [s–1] 0.72 ± 0.2 1.08 ± 0.26 < 0.005
Septal SS [%] 16 ± 4.3 20.1 ± 5.3 < 0.005
Lateral SS [%] 14 ± 6.1 18.2 ± 5.6 < 0.005
SSR — systolic strain rate; SS — peak systolic strain; NS — non significant
Table 3. Findings before and after anthracycline therapy in all study patients.
Before ANT therapy (n = 80) After ANT therapy (n = 80) P 
Left atrium diameter [mm] 32.4 ± 4.9 33.8 ± 5.9 NS
Interventricular septum diameter [mm] 10.2 ± 1.2 10.2 ± 1.1 NS
Posterior wall diameter [mm] 9.3 ± 1.3 9.2 ± 1.3 NS
Left ventricular diastolic size [mm] 44.7 ± 3.7 44.3 ± 3.6 NS
Left ventricular systolic size [mm] 27.6 ± 5.1 27.8 ± 4.7 NS
Ejection fraction 65.5 ± 5.1 63.8 ± 5 NS
Fractional shortening 40.8 ± 5.1 40.4 ± 4.7 NS
E [m/s] 77.7 ± 16.1 76.7 ± 17.1 NS
A 66.3 ± 15 66.7 ± 13 NS
Isovolumic relaxation time 64.1 ± 17.9 66.1 ± 17.8 NS
E/A 1.4 ± 0.3 1.3 ± 0.3 NS
Septal S 7.15 ± 1.2 7.08 ± 1 NS
Lateral S 8.9 ± 1.9 8.8 ± 2 NS
Septal SSR [s–1] 0.93 ± 0.17 0.81 ± 0.18 0.008
Lateral SSR [s–1] 1.07 ± 0.19 0.87 ± 0.2 < 0.005
Septal SS [%] 19.7 ± 3.7 18 ± 4.7 0.03
Lateral SS [%] 17.6 ± 4.1 16.1 ± 5.8 0.05
SSR — systolic strain rate; SS — peak systolic strain; NS — non significant
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Strain imaging
Strain imaging parameters were comparable 
between groups at baseline, and were within 
normal limits (Table 1). The septal and lateral 
systolic strain and strain rate values, which de-
monstrate longitudinal myocardial function, were 
significantly decreased in control patients compa-
red to the carvedilol group following 6 months of 
ANT therapy (Table 2). In addition, the septal and 
lateral systolic strain and strain rate values were 
decreased significantly in control echocardiography 
compared to baseline echocardiography (Table 3).
Discussion
This randomized, controlled study evaluated 
the protective role of carvedilol in the development 
of silent AIC in patients with breast cancer. With 
a follow-up time of 6 months, it was possible to detect 
the early side-effects of AIC. Our major finding was 
that SI was significantly decreased in the control 
group compared to the carvedilol group following 
ANT therapy. However, the echocardiographic pa-
rameters identifying LV function were not different 
between the groups. Interpretations of our findings 
have included the fact that ANT-cardiomyopathy 
(CMP) may have a regional pattern; thus the 
function of some myocardial segments may com-
pensate for dysfunctional segments leading to 
a preserved LVEF in the early stages of cardioto-
xicity. Another possible contributing factor to the 
higher sensitivity of strain compared to the LVEF 
may be the difference in inter-observer variability.
Echocardiography is one of the most widely 
used noninvasive methods for the early detection 
and monitoring of ANT-induced CMP [10]. Early 
detection is of paramount importance as it allows 
for the use of cardioprotective agents. Longitu-
dinal myocardial function may be impaired while 
systolic function remains normal. Standard gray-
-scale imaging not only allows the assessment of 
cardiac structure, but also provides information on 
myocardial function. Standard echocardiographic 
measurements, such as endocardial FS and EF, 
reflect the chamber dynamics and are not direct 
measurements of longitudinal function. As many 
diseases result in the regional dysfunction of the 
ventricle, ultrasonograhic assessment of regional 
myocardial dysfunction remains an important 
goal in clinical cardiology [11, 12]. Recent studies 
showed that strain- and strain rate-imaging were 
more sensitive indices in identifying ANT-induced 
myocardial systolic changes than standard echocar-
diographic parameters [13, 14]. Stoodley et al. [15] 
revealed that while greater than 10% reductions 
in longitudinal and radial peak LV strain measure-
ments were observed following ANT therapy in 
half of the participants, a corresponding reduction 
in EF of greater than 10% was not observed in 
any of the participants. Further, Sawaya et al. [16] 
recently reported that reduced longitudinal and 
radial strain following 3 months of cancer treatment 
could predict the development of cardiotoxicity, 
while reduced EF following 3 months could not.  
Several hypotheses have been advanced to 
explain AIC. Most involve the generation of re-
active oxygen species, which induce apoptosis 
and cardiac myocyte damage [17]. Other mecha-
nisms implicated in the pathogenesis AIC include 
lipid peroxidation, gene expression reduction, 
nucleic acid and protein synthesis inhibition, 
adrenergic function alteration and disruption of 
mitochondrial Ca2+ homeostasis [18–20]. ANT 
side effects are cumulatively dose dependent and 
irreversible. The risk of developing ANT-induced 
CMP is affected by many factors including age, 
concomitant use of other chemotherapeutics and 
targeted therapy agents (e.g., trastuzumab), prior 
irradiation exposure, underlying heart disease 
and high cumulative doses [21]. In addition, the 
incidence of ANT-induced CMP largely depends 
on the type of chemotherapeutic agent being used 
(e.g., epirubicin and liposomal doxorubucin are less 
cardiotoxic than adriamycin). Several methods, 
including pharmacokinetic modification by liposo-
mal encapsulation, alteration of chemical structure 
leading to drugs such as epirubicin, altering drug 
infusion, and attenuation of iron chelation through 
pretreatment with dexrazoxane have been asso-
ciated with a reduction in cardiovascular events 
in ANT treated patients; however most of these 
strategies are not in common practice in the clinical 
setting [22]. Beta-blockers have been considered 
agents for the treatment of systolic heart failure 
[23]. Beneficial effects of carvedilol on morbidity 
and all-cause mortality have been demonstrated in 
heart failure patients [24]. Few reports are availab-
le on the cardioprotective use of beta-blockers in 
patients receiving ANT [8, 25]. Trials conducted 
among limited number of patients have shown that 
co-administration of carvedilol during ANT therapy 
could prevent ANT-induced CMP. Additionally, 
Jonnson et al. [26] showed that carvedilol does 
not reduce the effectiveness of anti-neoplastics, 
which is an important consideration if it is to be 
administered together with ANT. The mechanisms 
behind the protective effect of carvedilol against 
ANT-induced CMP were not fully explained, but 
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it is assumed to be due to the antioxidant action 
of carvedilol and its metabolites [27]. Other po-
ssible mechanisms include: restoration of the 
activity of the sarcoplasmic reticulum Ca-ATPase 
(SERCA2) in myocytes, the expression inhibition 
of the SERCA2 suppressor gene [28, 29]. Additio-
nally, carvedilol treatment is associated with the 
inhibition of the apoptotic signaling pathway [8]. 
However, at present, there is no phase III trial data 
that strongly encourages the routine prophylactic 
administration of carvedilol for protection against 
ANT-induced CMP.  
In light of the above mentioned facts, the 
protective effect of carvedilol could be detected 
more sensitively by SI. The present study showed 
that co-administration of carvedilol during ANT 
therapy preserves several subtle abnormalities 
in myocardial function that were detected in the 
asymptomatic period and normal EF, as identi-
fied by SI. The results of our study indicate that 
carvedilol treatment has some protective effects 
againist AIC in the short-term but we can not 
extrapolate our results to the long-term because 
of the short follow-up of our study. While EF and 
FS were similar in both group echocardiographies, 
septal and lateral systolic strain and strain rate 
values were significantly lower in control patients 
compared to the carvedilol group. The significant 
reduction in SI parameters was in agreement with 
the results of ANT-induced therapy in children 
described in Ganame et al. [30]. In addition there 
were no significant differences in diastolic func-
tion measured after ANT therapy in our patients. 
Similar results were reported by Ewer et al. [31] 
and El-Shitany et al [25]. 
Limitations of the study
Our study has several limitations; including its 
open label design, and the relatively small sample 
size. However the detection of subtle changes in 
myocardium of breast cancer patients exposed 
to ANT with SI and reversal of these deleterious 
effects with carvedilol is a promising finding for 
future therapeutical interventions.   
Conclusions
The preventative effect of carvedilol on lon-
gitudinal LV systolic function during ANT therapy 
may be documented by strain rate imaging, which 
is afterload independent at a time when the other 
parameters obtained from standard M-mode echo-
cardiographic analysis remain normal. Our results 
will require long-term follow-up evaluations for 
future cardiovascular events in the carvedilol 
patient group. 
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